<strong class="sub-title"> Background: </strong> Adipokines are adipose tissue-derived secreted molecules that can exert anti-inflammatory or proinflammatory activities. Altered expression of adipokines has been described in various inflammatory diseases, including inflammatory bowel diseases (IBDs) such as Crohn's disease (CD) and ulcerative colitis (UC). Little is known about <em>nesfatin</em>-<em>1</em>, a recently identified adipokine, in IBD. The aim of this study was to investigate serum <em>nesfatin</em>-<em>1</em> levels in patients with IBD.

<strong class="sub-title"> Methods: </strong> This study included a total of 52 adult individuals (<em>1</em>7 patients with CD, <em>1</em>8 patients with UC and <em>1</em>7 healthy volunteers) with similar age and body mass index. Serum <em>nesfatin</em>-<em>1</em> levels were measured by ELISA in healthy individuals and patients with IBD in their active and remission periods. Blood inflammation markers including C reactive protein (CRP), erythrocyte sedimentation (ESR) and white cell count (WCC) were also measured in patients.

<strong class="sub-title"> Results: </strong> We found significantly elevated levels of serum <em>nesfatin</em>-<em>1</em> in the active disease period in both patients with CD (p=0.00003) and patients with UC (p=0.0000<em>1</em>), compared with healthy individuals. Serum <em>nesfatin</em>-<em>1</em> levels moderately decreased in the remission period; however, they were still significantly higher than that of healthy individuals. Receiver operating characteristic curve analyses indicated serum <em>nesfatin</em>-<em>1</em> with an excellent diagnostic value for IBD. Finally, patients had significantly high CRP, ESR and WCC in the active IBD; however, we found the <em>nesfatin</em>-<em>1</em> strongly correlated only with ESR in the active CD.

<strong class="sub-title"> Conclusion: </strong> This is the first study investigating the circulating levels of <em>nesfatin</em>-<em>1</em> in patients with IBD. Serum <em>nesfatin</em>-<em>1</em> may serve as an additional inflammatory marker for diagnosis of IBD in affected individuals.

Keywords: adult gastroenterology; gastroenterology; inflammatory bowel disease.

The vast majority of new neuropeptides feature unique biochemical properties as well as awide spectrum of physiological activity applied in numerous neuronal pathways, including hypothalamus and the limbic system. Special interest should be paid to <em>nesfatin</em>-<em>1</em> - the relatively recently discovered and still intensively studied regulatory factor and a potential modulator of eating behaviors. New information about it now allows to consider this neuropeptide as a potentially important factor involved in the pathogenesis of many different mental disorders. The considered pharmacomodulation of <em>nesfatin</em>ergic signaling may be potentially helpful in the future treatment of some neuropsychiatric and metabolic disorders including anorexia nervosa. Although the results of some basic and clinical tests seem to be promising, all possible applications of the aforementioned neuropeptides, together with their agonists and antagonists still remain in the area of speculation. The intensive search of selective modulators of their known receptors may facilitate the opening of a promising chapter in the eating disorders therapy. This paper provides a review of recent scientific reports regarding the hypothetical role of <em>nesfatin</em>-<em>1</em> in the neuronal pathways related to pathophysiology of anorexia nervosa.

Keywords: anorexia nervosa; hypothalamus; neuropeptides.

<strong class="sub-title"> Background: </strong> Nonalcoholic fatty liver disease (NAFLD) is a serious and widespread disease worldwide. Bariatric surgery is one of the treatments for NAFLD. <em>Nesfatin</em>-<em>1</em> is located in the brain, periphery and plasma. We studied the relationship between <em>nesfatin</em>-<em>1</em> changes after laparoscopic sleeve gastrectomy (LSG) and NAFLD remission.

<strong class="sub-title"> Methods: </strong> A total of 29 patients participated in the study, which collected clinical information on the patients and indicators of liver function, hepatic steatosis score and <em>nesfatin</em>-<em>1</em> level before and after LSG.

<strong class="sub-title"> Results: </strong> The average BMI of the patients before surgery was 42.63±8.9<em>1</em> kg/m², and the average BMI was 28.54±5.63 kg/m² one year after surgery (p < 0.05). One year after LSG, the total weight loss percentage (TWL%) was 32.<em>1</em><em>1</em>±7.<em>1</em>0%. The mean value of <em>nesfatin</em>-<em>1</em> before surgery was 3.04±0.8<em>1</em> ng/mL, and the mean value of <em>nesfatin</em>-<em>1</em> was 5.52±<em>1</em>.55 ng/mL at one year after surgery (p < 0.05). The average preoperative hepatic steatosis index (HSI) score of the patients was 52.55±9.<em>1</em>7, and the average postoperative HSI score was 38.84±5.82 (p < 0.05). Before LSG (p < 0.05, r= -0.8<em>1</em>) and <em>1</em> year after surgery (p < 0.05, r = -0.58), HSI and <em>nesfatin</em>-<em>1</em> were significantly negatively correlated. Percentage of increased <em>nesfatin</em>-<em>1</em> and percentage of decreased HSI showed positive correlation after LSG.

<strong class="sub-title"> Conclusion: </strong> There was a negative correlation between HSI and <em>nesfatin</em>-<em>1</em> before and after LSG, which may suggest that <em>nesfatin</em>-<em>1</em> plays a role in NAFLD.

<strong class="sub-title"> Keywords: </strong> LSG; NAFLD; bariatric surgery; <em>nesfatin</em>-<em>1</em>.

Background: Roux-en-Y gastric bypass (RYGB) could reduce nonalcoholic fatty liver disease (NAFLD) ahead of the weight-loss effects. But the detailed mechanisms remain unclear.

<strong class="sub-title"> Material and methods: </strong> A high-fat diet (HFD) was fed to induce obesity. RYGB was then performed. Gastric <em>nesfatin</em>-<em>1</em> was measured by enzyme-linked immunosorbent assay (ELISA) in portal vein and polymerase chain reaction (PCR) in gastric tissues. Modified surgeries including vagus-preserved bypass and vagectomy were performed and postprandial gastric <em>nesfatin</em>-<em>1</em> were analyzed. The effects of <em>nesfatin</em>-<em>1</em> on hepatocytes were studied by PCR and immunohistochemistry. Both intraperitoneal and intracerebroventricular injection (ICV) were performed to analyze the in vivo effects on liver lipid metabolism.

<strong class="sub-title"> Results: </strong> Increased postprandial portal vein <em>nesfatin</em>-<em>1</em> was observed in RYGB but not in control groups. This increase is mainly due to induction of gastric <em>nesfatin</em>-<em>1</em>. A modified RYGB in which the gastric vagus is preserved is conducted and, in this case, this <em>nesfatin</em>-<em>1</em> induction effect is diminished. Mere vagectomy could also induce a similar <em>nesfatin</em>-<em>1</em> increase pattern. The infusion of <em>nesfatin</em>-<em>1</em> in the brain could inhibit the expression of gastric <em>nesfatin</em>-<em>1</em>, and the effects are diminished after gastric vagectomy. In vivo and in vitro <em>nesfatin</em>-<em>1</em> stimulation in the liver resulted in improvements in lipid metabolism.

<strong class="sub-title"> Conclusions: </strong> Severing the gastric vagus during RYGB could cut off the negative control from the central nervous system (CNS) and result in increased postprandial gastric <em>nesfatin</em>-<em>1</em> post surgery, which in turn, improves NAFLD.

<strong class="sub-title"> Purpose of review: </strong> Ghrelin was discovered in <em>1</em>999; extensive research and clinical studies on ghrelin have been published in the last 20 years. Physiological research on ghrelin ranges from its appetite-stimulating effects to its association with energy homeostasis. The physiological effects of ghrelin in the gastrointestinal tract and its relevance in the pathological conditions of the gastrointestinal tract have gradually become clearer. The purpose of the review is to provide current information on ghrelin cell biology and physiology, particularly in the gastrointestinal tract.

<strong class="sub-title"> Recent findings: </strong> Ghrelin-producing cells in the stomach are characterized as X/A-like cells, but immunohistochemical analyses have revealed co-expression of several secreted proteins and hormones in ghrelin-producing cells such as <em>nesfatin</em>-<em>1</em>, somatostatin, and pancreastatin. Furthermore, the local physiological roles and/or mechanisms of ghrelin in gastrointestinal functions such as gastric motility and inflammation are discussed.

Summary: Ghrelin is a brain-gut hormone with a wide range of physiological actions; hence, it is important to understand its effects on the physiological functions of the gastrointestinal tract to elucidate the biological significance of ghrelin.

Introduction: Severe local and systemic tissue injury develop during reperfusion, which is a period during which arterial blood flow and tissue oxygenation are re-established. In this study, we aimed to investigate the anti-inflammatory, antioxidant and protective effects of nesfatin in IR damage developing in liver.

<strong class="sub-title"> Material and methods: </strong> Twenty-four male Wistar-Albino rats were divided to three groups which contained eight rats in all groups. The rats were subjected to 30 minutes of hepatic pedicule occlusion followed by 2h of reperfusion to induce I/R damage. <em>Nesfatin</em><em>1</em> (<em>1</em>0 μg/ kg) was administered, 30 min prior to ischemia and immediately before the reperfusion period.

<strong class="sub-title"> Results: </strong> The findings showed that while the blood levels of AST, ALT and LDH were markedly elevated in the I/R group, they returned to normal levels upon treatment in the <em>Nesfatin</em> group. While IL-<em>1</em> α, IL-<em>1</em>β, IL-6, TNF-α and IFN- γ levels in blood and tissue were lower after therapy in the <em>Nesfatin</em> group compared to the I/R group, statistically significant decreases were only noted in IL-<em>1</em>β, IL-6, TNF-α and IFN- γ levels. TAS levels increased in the treatment group, while upon <em>nesfatin</em> treatment statistically significant decreases were noted in TOS and OSI levels. Histopathological investigations also showed statistically significant decreases in Bax and Caspase-3 staining intensity and the number of stained cells in the <em>Nesfatin</em> group.

Conclusion: The nesfatin has antioxidant activity and anti-inflammatory effect on improvement of liver functions and histopathological findings in liver ischemia and reperfusion injury.

<strong class="sub-title"> Key words: </strong> Anti-inflammatory, Anti apoptotic Liver ischemia-reperfusion injury, <em>Nesfatin</em>-<em>1</em>.

Durante la riperfusione, con il ripristino del flusso ematico arterioso e l’ossigenazione dei tessuti, si sviluppa una grave lesione tissutale locale e sistemica. In questo studio, abbiamo indagato sperimentalmente gli effetti antiinfiammatori, antiossidanti e protettivi di <em>nesfatin</em> in relazione al danno ischemia/riperfusione (I/R) che si sviluppa nel fegato. Per questo studio sono stati impiegati 24 ratti Wistar- Albino maschi, divisi in tre gruppi di otto individui ciascuno. I ratti sono stati sottoposti a 30 minuti di occlusione del peduncolo epatico seguiti da 2 ore di riperfusione per indurre il danno I / R. <em>Nesfatin</em><em>1</em> è stata somministrata alla dose di <em>1</em>0 μg / kg, 30 minuti prima dell’induzione dell’ischemia e immediatamente prima del periodo di riperfusione nel 3° gruppo, mentre il primo gruppo è stato utilizzato come controllo senza clampaggio del peduncolo, ed il secondo è stato sottoposto a 30’ di ischemia per clampaggio senza somministrazione di <em>Nesfatin</em>. . I risultati hanno mostrato che mentre i livelli ematici di AST, ALT e LDH erano marcatamente elevati nel gruppo I / R, ritornavano a livelli normali dopo trattamento nel gruppo <em>Nesfatin</em>. Mentre i livelli di IL-<em>1</em> α, IL- <em>1</em>β, IL-6, TNF-α e IFN-γ nel sangue e nei tessuti erano inferiori dopo la terapia nel gruppo <em>Nesfatin</em> rispetto al gruppo I / R, le diminuzioni statisticamente significative sono state osservate solo in IL Livelli -<em>1</em>β, IL-6, TNF-α e IFN-γ. I livelli di TAS sono aumentati nel gruppo di trattamento, mentre sul trattamento con <em>nesfatin</em> sono state notate diminuzioni statisticamente significative nei livelli TOS e OSI. Le indagini istopatologiche hanno anche mostrato diminuzioni statisticamente significative dell’intensità di colorazione di Bax e Caspase-3 e il numero di cellule colorate nel gruppo <em>Nesfatin</em>. L’attività antiossidante e l’effetto anti-infiammatorio del <em>nesfatin</em> determina dunque un miglioramento delle funzioni epatiche e dei risultati istopatologici nell’ischemia epatica e nel danno da riperfusione.

The present study investigated the effects of <em>nesfatin</em>-<em>1</em> on gastric distension (GD)-responsive neurons via an interaction with corticotropin-releasing factor (CRF) receptor signaling in the ventromedial hypothalamic nucleus (VMH), and the potential regulation of these effects by hippocampal projections to VMH. Extracellular single-unit discharges were recorded in VHM following administration of <em>nesfatin</em>-<em>1</em>. The projection of nerve fibers and expression of <em>nesfatin</em>-<em>1</em> were assessed by retrograde tracing and fluoro-immunohistochemical staining, respectively. Results showed that there were GD-responsive neurons in VMH; <em>Nesfatin</em>-<em>1</em> administration and electrical stimulation of hippocampal CA<em>1</em> sub-region altered the firing rate of these neurons. These changes could be partially blocked by pretreatment with the non-selective CRF antagonist astressin-B or an antibody to NUCB2/<em>nesfatin</em>-<em>1</em>. Electrolytic lesion of CA<em>1</em> hippocampus reduced the effects of <em>nesfatin</em>-<em>1</em> on VMH GD-responsive neuronal activity. These studies suggest that <em>nesfatin</em>-<em>1</em> plays an important role in GD-responsive neuronal activity through interactions with CRF signaling pathways in VMH. The hippocampus may participate in the modulation of <em>nesfatin</em>-<em>1</em>-mediated effects in VMH.

<AbstractText><em>Nesfatin</em>-<em>1</em>, processed from nucleobindin-2 (NUCB2), is a potent anorexigenic peptide being expressed in rodent hypothalamic nuclei and involved in the regulation of feeding behavior and body weight in animals. The present study aimed to investigate NUCB2/<em>nesfatin</em>-<em>1</em> protein expression in the human hypothalamus as well as its correlation with body weight.</AbstractText><AbstractText>Sections of hypothalamus and adjacent cholinergic basal forebrain nuclei, including the nucleus basalis of Meynert (NBM) and the diagonal band of Broca (DBB), from 25 autopsy cases (<em>1</em>7 males, 8 females; 8 lean, 9 overweight, 8 obese) were examined using immunohistochemistry and double immunofluorescence labeling.</AbstractText><AbstractText>Prominent NUCB2/<em>nesfatin</em>-<em>1</em> immunoexpression was detected in supraoptic, paraventricular, and infundibular nuclei, lateral hypothalamic area (LHA)/perifornical region, and NBM/DBB. NUCB2/<em>nesfatin</em>-<em>1</em> was found to extensively colocalize with (a) oxytocin and vasopressin in paraventricular and supraoptic nuclei, (b) melanin-concentrating hormone in the LHA, and (c) cocaine- and amphetamine-regulated transcript in infundibular and paraventricular nuclei and LHA. Interestingly, in the LHA, NUCB2/<em>nesfatin</em>-<em>1</em> protein expression was significantly decreased in obese, compared with lean (p < 0.0<em>1</em>) and overweight (p < 0.05) subjects.</AbstractText><AbstractText>The findings of the present study are suggestive of a potential role for NUCB2/<em>nesfatin</em>-<em>1</em> as an integral regulator of food intake and energy homeostasis in the human hypothalamus. In the LHA, an appetite- and reward-related brain area, reduced NUCB2/<em>nesfatin</em>-<em>1</em> immunoexpression may contribute to dysregulation of homeostatic and/or hedonic feeding behavior and obesity. NUCB2/<em>nesfatin</em>-<em>1</em> localization in NBM/DBB might imply its participation in the neuronal circuitry controlling cognitive influences on food intake and give impetus towards unraveling additional biological actions of NUCB2/<em>nesfatin</em>-<em>1</em> in human neuronal networks.</AbstractText>

The present study was designed to determine the effect of central injection of <em>Nesfatin</em>-<em>1</em> and corticotropin and histaminergic systems on food intake in neonatal meat-type chicks. In this study, 7 experiments were designed, each with 4 treatment groups. In experiment <em>1</em>, four groups of chicks received the ICV injection of (A) phosphate-buffered saline (PBS), (B) <em>Nesfatin</em>-<em>1</em> (<em>1</em>0 ng), (C) <em>Nesfatin</em>-<em>1</em> (20 ng) and (D) <em>Nesfatin</em>-<em>1</em> (40 ng). In experiment 2, (A) PBS, (B) Astressin-B (CRF<em>1</em>/CRF2 receptors antagonist; 30 µg), (C) <em>Nesfatin</em>-<em>1</em> (40 ng) and (D) <em>Nesfatin</em>-<em>1</em> + Astressin-B were injected. In experiments 3-6, chicken received ICV injection of the Astressin2-B (CRF2 receptor antagonist; 30 µg), α-FMH (alpha fluoromethyl histidine; as inhibitor of histidine decarboxylase, 250 nmol), Chlorpheniramine (histamine H<em>1</em> receptors antagonist, 300 nmol), Famotidine (histamine H2 receptors antagonist, 82 nmol) and Thioperamide (histamine H3 receptors antagonist, 300 nmol) instead of the Astressin-B. Then the cumulative food intake measured until <em>1</em>20 min post-injection. According to the results, ICV injection of <em>Nesfatin</em>-<em>1</em> dose dependently decreased food intake in neonatal chicks (P < 0.05). Co-injection of the <em>Nesfatin</em>-<em>1</em> and Astressin-B (CRF<em>1</em>/CRF2) inhibited <em>Nesfatin</em>-<em>1</em> induced hypophagia (P < 0.05). ICV inejction of the <em>Nesfatin</em>-<em>1</em> + Astressin-B significantly inhibited the effect of <em>Nesfatin</em>-<em>1</em> on food intake (P < 0.05). In addition, α-FMH and chlorpheniramine attenuated <em>Nesfatin</em>-<em>1</em>-induced hypophagia in chicks (P < 0.05); while thioperamide significantly amplified the effect of <em>Nesfatin</em>-<em>1</em> on food intake in chicks (P < 0.05). These results suggested <em>Nesfatin</em>-<em>1</em> has an anorectic effect in 3-hour food deprived neonatal meat-type chicks and this effect was mediated by corticotropin CRF<em>1</em>/CRF2 as well as histamine H<em>1</em> and H3 receptors.

<em>Nesfatin</em>-<em>1</em> is a peptide derived from the nucleobindin 2 (<i>Nucb2</i>) precursor protein that has been shown to exert potent effects on appetite and cardiovascular function in male animals. Sex hormones modulate the expression of <i>Nucb2</i> in several species, including goldfish, mouse, and rat, and human studies have revealed differential expression based on male or female sex. We therefore hypothesized that the ability of <em>nesfatin</em>-<em>1</em> to increase mean arterial pressure (MAP) would be influenced by stage of the estrous cycle. Indeed, we found that in cycling female Sprague-Dawley rats, <em>nesfatin</em>-<em>1</em> induced an increase in MAP on diestrus, when both estrogen and progesterone levels are low but not on proestrus or estrus. The effect of <em>nesfatin</em>-<em>1</em> on MAP was dependent on functional central melanocortin receptors, because the <em>nesfatin</em>-<em>1</em>-induced increase in MAP was abolished by pretreatment with the melanocortin 3/4 receptor antagonist, SHU9<em>1</em><em>1</em>9. We previously reported that <em>nesfatin</em>-<em>1</em> inhibited angiotensin II-induced water drinking in male rats but found no effect of <em>nesfatin</em>-<em>1</em> in females in diestrus. However, <em>nesfatin</em>-<em>1</em> enhanced angiotensin II-induced elevations in MAP in females in diestrus but had no effect on males. Finally, in agreement with previous reports, the expression of <i>Nucb2</i> mRNA in hypothalamus was significantly reduced in female rats in proestrus compared with rats in diestrus. From these data we conclude that the function and expression of <em>nesfatin</em>-<em>1</em> are modulated by sex hormone status. Further studies are required to determine the contributions of chromosomal sex and individual sex hormones to the cardiovascular effects of <em>nesfatin</em>-<em>1</em>.

<strong class="sub-title"> Background: </strong> Galectin-<em>1</em>, haptoglobin, and <em>nesfatin</em>-<em>1</em> have recently emerged as promising biomarkers implicated in immunometabolism. However, whether single blood measurements of these analytes could be suitable for large-scale human studies has not yet been evaluated.

<strong class="sub-title"> Methods: </strong> The concentrations of galectin-<em>1</em>, haptoglobin, and <em>nesfatin</em>-<em>1</em> were measured over a 4-month period in 207 healthy adults with median age of 56.7 years. Biomarker intra-individual reproducibility was assessed based on calculation of intraclass correlation coefficients (ICCs) and examining Bland-Altman plots.

<strong class="sub-title"> Results: </strong> The overall ICCs were excellent for <em>nesfatin</em>-<em>1</em> (ICC: 0.89 (95% CI: 0.86, 0.92), and good for galectin-<em>1</em> and haptoglobin (ICCs: 0.70 (95% CI: 0.6<em>1</em>, 0.77) and 0.67 (95% CI: 0.57, 0.74), respectively). Bland-Altman plots supported a high level of agreement between repeated biomarker measurements.

<strong class="sub-title"> Conclusions: </strong> Assay measurements of galectin-<em>1</em>, haptoglobin, and <em>nesfatin</em>-<em>1</em> showed good to excellent within-subject reproducibility over a 4-month period, indicating that they may serve as feasible and reliable biomarkers for assessing metabolic inflammation in population research.

<strong class="sub-title"> Keywords: </strong> BMI, body mass index; ELISA– Enzyme-Linked Immunosorbent Assay. Hb, hemoglobin. hsCRP; EPIC, European Prospective Investigation into Cancer and Nutrition; IQR, interquartile range; Intra-individual reproducibility; Repeated measurements; galectin-<em>1</em>; haptoglobin; high sensitivity C-reactive protein. ICC, intraclass correlation coefficient; <em>nesfatin</em>-<em>1</em>.

Prolactin (PRL), mainly synthesized and secreted by the lactotrophs and somatolactotrophs of the anterior pituitary, is a pleiotropic hormone that regulates lactation. In the last decade, <em>nesfatin</em>-<em>1</em> (NESF) and NESF-like peptide (NLP), encoded in nucleobindin <em>1</em> and 2 (NUCB<em>1</em> and NUCB2), respectively, were characterized as metabolic factors with a potential role in the control of pituitary hormones. We hypothesized that NUCBs and their encoded peptides (NESF and NLP) suppress PRL transcription in the pituitary. The main objective of this research was to determine whether exogenous NESF and NLP, and/or endogenous NUCB<em>1</em> and NUCB2 regulate the expression of prl and preb mRNAs. Using immortalized rat somatolactotrophs (GH3 cells), dose-dependent studies were performed to test whether NESF and NLP affect prl and preb. Moreover, the ability of these peptides to modulate the effects of the PRL stimulator thyrotropin releasing hormones (TRH) was studied. Besides, the effects of siRNA-mediated knockdown of endogenous NUCBs on prl and preb mRNAs were determined. NESF and NLP reduced the transcription of prl and preb in GH3 cells. Both NESF and NLP also prevented the stimulatory effects of TRH prl and preb expression. The attenuation of endogenous NUCB<em>1</em> attenuates both basal prl and TRH-induced expression of prl and preb, while the silencing of NUCBs did not affect the actions of exogenous NESF or NLP. Overall, this work reveals that NUCBs and encoded-peptides are novel regulators of PRL. Future research should test whether the effects observed here in GH3 cells are preserved both in vivo and at the post-transcriptional level.

<strong class="sub-title"> Keywords: </strong> NLP; NUCB<em>1</em>; NUCB2; Nesfatin-<em>1</em>; PREB; Prolactin.

<strong class="sub-title"> Background: </strong> Copeptin and <em>nesfatin</em>-<em>1</em> have recently been identified as novel peptides that play a role in the pathogenesis of obesity-related insulin resistance in adults. However, the relationship between them has not yet been elucidated, and their circulating levels in children with obesity have not been adequately studied. Therefore, the current study aimed to investigate whether their levels are altered in Chinese children with obesity, as well as to determine the correlation of these 2 peptides with each other, with insulin resistance, and with other biochemical parameters.

<strong class="sub-title"> Methods: </strong> A total of <em>1</em>56 children were enrolled in this study, including <em>1</em>0<em>1</em> children with obesity and 55 lean controls. Anthropometric parameters and clinical data of all subjects were collected, and circulating tumor necrosis factor-α, adiponectin, leptin, copeptin, and <em>nesfatin</em>-<em>1</em> levels were measured using ELISA.

<strong class="sub-title"> Results: </strong> Serum copeptin and <em>nesfatin</em>-<em>1</em> levels were significantly elevated in children with obesity and children with insulin resistance compared to control subjects. In addition, <em>nesfatin</em>-<em>1</em> and copeptin levels were found to be significantly positively correlated with one another by Pearson's correlation and partial correlation. In multiple regression analysis using <em>nesfatin</em>-<em>1</em> or copeptin as the dependent parameter, a significant correlation was observed between <em>nesfatin</em>-<em>1</em> and copeptin, and associations between each of them with homeostasis model assessment of insulin resistance (HOMA-IR) were detected.

Conclusion: These novel findings shed light on the possible interplay role of these 2 molecules in obesity-related insulin resistance.

<strong class="sub-title"> Keywords: </strong> Children with obesity; Copeptin; Insulin resistance; Nesfatin-<em>1</em>.

<AbstractText><em>Nesfatin</em>-<em>1</em>, an anorexigenic peptide, has been associated with food intake and thermogenesis, with discordant findings in humans and scarce studies in children to date.</AbstractText><AbstractText>The aim of this study was to analyze the relationship of obesity with <em>nesfatin</em>-<em>1</em> levels in two cohorts of children.</AbstractText><AbstractText>Plasma <em>nesfatin</em>-<em>1</em> concentrations were analyzed in 6- to 9-year-olds (n = <em>1</em>40) and <em>1</em>2- to <em>1</em>6-year-old children (n = 96), including children with obesity and their sex- and age-matched normal-weight counterparts. Anthropometric measurements were assessed. Cholesterol and triglycerides were determined enzymatically, insulin concentrations were measured by radioimmunoassay using a commercial kit and <em>nesfatin</em>-<em>1</em>, leptin and hs-CRP concentrations were determined using commercial ELISA kits.</AbstractText><AbstractText><em>Nesfatin</em>-<em>1</em> concentrations were significantly lower in younger (P = .00<em>1</em>) and older (P = .009) girls with obesity than in their normal-weight counterparts, without showing significant differences in boys. <em>Nesfatin</em>-<em>1</em> showed a negative significant (P < .0<em>1</em>0) correlation with weight and BMI in girls but not in boys. A significant positive correlation of <em>nesfatin</em>-<em>1</em> levels with insulin, HOMA, and leptin levels appears in girls after adjusting by age and BMI. A significant positive correlation (P = .003) was observed between <em>nesfatin</em>-<em>1</em> and fat mass in older children.</AbstractText><AbstractText>Our study shows lower concentrations of <em>nesfatin</em>-<em>1</em> related to obesity in girls but not in boys at two different ages. The existence of a sex-specific association between <em>nesfatin</em>-<em>1</em> concentrations and presence of obesity highlights the need of an analysis by gender of the relationship of <em>nesfatin</em>-<em>1</em> with obesity.</AbstractText>

BACKGROUND

As a recently discovered adipokine, <em>nesfatin</em>-<em>1</em> is conducive to insulin sensitivity, lipid profile, energy balance, and probably obesity.

OBJECTIVE

The aim of the present study was to investigate the effect of upper-body resistance exercise training (RET) on <em>nesfatin</em>-<em>1</em> levels, insulin resistance, lipid profile, and body composition in obese paraplegic men.

METHODS

Twenty obese paraplegic men were randomly assigned into control and upper-body RET groups. Upper-body RET was performed for 8 weeks, 3 sessions per week at an intensity corresponding to 60-80% maximum amount of force that can be generated in one maximal contraction in 5 stations (bench press, seated rows, sitting lat pulldown, arm extension, and arm curls). Body fat percentage was determined according to 4-sites skinfold protocol of Durnin and Womersley and Siri equation. Obesity for spinal cord injury patients in the current study was set at BMI >22 kg/m2. Data were statistically analyzed by paired and independent t-test (P < 0.05).

RESULTS

We found significant improvements in serum levels of <em>nesfatin</em>-<em>1</em> (2<em>1</em>.<em>1</em>3%), insulin sensitivity (8.95%), and high-density lipoprotein (<em>1</em>0.87%). Other lipid profile markers, i.e. low-density lipoprotein (4.32%), cholesterol (8.20%), and triglyceride (<em>1</em>5.<em>1</em>0%) reduced significantly after upper-body RET. Moreover, upper-body RET led to a significant reduction in body mass index (2.36%), body fat percentage (2.79%), and waist-to-hip ratio (2.40%).

CONCLUSIONS

Upper-body RET improved insulin sensitivity, lipid profile, and body composition in paraplegic men. Serum nefastin-<em>1</em> may be a potential marker of success in weight management in this population.

Chronic hypernatremia activates the central osmoregulatory mechanisms and inhibits the function of the hypothalamic-pituitary-adrenal (HPA) axis. Noradrenaline (NE) release into the periventricular anteroventral third ventricle region (AV3V), the supraoptic (SON) and hypothalamic paraventricular nuclei (PVN) from efferents of the caudal ventrolateral (cVLM) and dorsomedial (cDMM) medulla has been shown to be essential for the hypernatremia-evoked responses and for the HPA response to acute restraint. Notably, the medullary NE cell groups highly coexpress prolactin-releasing peptide (PrRP) and <em>nesfatin</em>-<em>1</em>/NUCB2 (<em>nesfatin</em>), therefore, we assumed they contributed to the reactions to chronic hypernatremia. To investigate this, we compared two models: homozygous Brattleboro rats with hereditary diabetes insipidus (DI) and Wistar rats subjected to chronic high salt solution (HS) intake. HS rats had higher plasma osmolality than DI rats. PrRP and <em>nesfatin</em> mRNA levels were higher in both models, in both medullary regions compared to controls. Elevated basal tyrosine hydroxylase (TH) expression and impaired restraint-induced TH, PrRP and <em>nesfatin</em> expression elevations in the cVLM were, however, detected only in HS, but not in DI rats. Simultaneously, only HS rats exhibited classical signs of chronic stress and severely blunted hormonal reactions to acute restraint. Data suggest that HPA axis responsiveness to restraint depends on the type of hypernatremia, and on NE capacity in the cVLM. Additionally, NE and PrRP signalization primarily of medullary origin is increased in the SON, PVN and AV3V in HS rats. This suggests a cooperative action in the adaptation responses and designates the AV3V as a new site for PrRP's action in hypernatremia.

<em>Nesfatin</em>-<em>1</em> was identified as a satiety factor involved in the regulation of metabolism. Altered levels of circulating <em>nesfatin</em>-<em>1</em> had been observed in a variety of diseases characterized by energy imbalance. However, there was no published data about <em>nesfatin</em>-<em>1</em> levels in acromegaly.We evaluated serum <em>nesfatin</em>-<em>1</em> levels in <em>1</em>3 patients with acromegaly at baseline and postoperatively, and in 2<em>1</em> age- and body mass index (BMI)-matched healthy subjects.Compared with the healthy subjects, patients with acromegaly had significantly increased levels of serum insulin, high-density lipoprotein cholesterol, triglyceride, and growth hormone (GH). Moreover, the acromegaly group had <em>nesfatin</em>-<em>1</em> levels higher than controls (<em>1</em>.96 ± 0.56 ng/mL vs 0.6<em>1</em> ± 0.<em>1</em>0 ng/mL, P = .004). There was a positive correlation of serum <em>nesfatin</em>-<em>1</em> levels with diastolic blood pressure (r = 0.579, P = .038) and homeostasis model assessment of insulin resistance (HOMA-IR) (r = 0.598, P = .03<em>1</em>) in patients with acromegaly. While a successful surgery decreased serum GH levels, the serum <em>nesfatin</em>-<em>1</em> levels did not change in acromegaly (P = .965). At last, we compared serum GH/<em>nesfatin</em>-<em>1</em> levels with predictive markers for aggressive behaviors in pituitary adenomas. There was no relationship between serum <em>nesfatin</em>-<em>1</em> levels and tumor's size, Ki-67 index, mutant p53, or MGMT proteins. However, increased serum GH levels were positively correlated with tumors' size (P = .023) and mutant p53 proteins expression (P = .028).Circulating <em>nesfatin</em>-<em>1</em> was increased in acromegaly, which was involved in metabolism regulation.

This cross-sectional study aimed to evaluate serum <em>nesfatin</em>-<em>1</em> concentrations in patients with erectile dysfunction (ED). Patients with ED were selected from the Department of Urology of the Second Affiliated Hospital of Anhui Medical University. The International Index of Erectile Function-5 (IIEF-5) was used to evaluate the severity of ED. Serum <em>nesfatin</em>-<em>1</em> and gonadal hormone levels, including luteinising hormone (LH), follicle-stimulating hormone (FSH) and testosterone were measured. The IIEF-5 scores (t = -2<em>1</em>.034, p < .00<em>1</em>) and <em>nesfatin</em>-<em>1</em> levels (t = -7.043, p < .00<em>1</em>) in patients with ED were significantly lower than in healthy controls. Moreover, patients with ED showed decreased testosterone levels (t = -3.478, p = .00<em>1</em>), whereas there were no significant differences in serum levels of FSH (t = -0.088, p = .930) and LH (t = <em>1</em>.<em>1</em><em>1</em>4, p = .270) between the two groups. Furthermore, positive relationships were found between serum <em>nesfatin</em>-<em>1</em> and testosterone concentrations (r = .742, p = .00<em>1</em>) and IIEF-5 scores (r = .395, p = .009) in ED patients. Additionally, based on receiver operating characteristic curve analysis, the area under curve for <em>nesfatin</em>-<em>1</em> was 0.884 with 83.3% sensitivity and 8<em>1</em>.4% specificity in discriminating ED patients from healthy controls. The decrease in serum <em>nesfatin</em>-<em>1</em> level may be related to testosterone and the severity of ED.

<strong class="sub-title">Keywords:</strong> erectile dysfunction; follicle-stimulating hormone; luteinising hormone; <em>nesfatin</em>-<em>1</em>; testosterone.

To analyze the correlation between IGF-<em>1</em>, ZAG, <em>nesfatin</em>-<em>1</em>, HbA<em>1</em>c levels, and type 2 diabetes mellitus (T2DM) complicated with hypothyroidism.Fifty-five patients with type-2 diabetes who were admitted to our hospital from August 20<em>1</em>8 to February 2020 were selected as the control group, and 55 patients with type 2 diabetes combined with hypothyroidism who were admitted to the hospital at the same period were selected as the combined group, and 56 patients who came to our hospital for physical examination at the same period were selected as the healthy group. The general clinical data and relevant laboratory indexes of all patients in the three groups were collected and statistically analyzed. Besides, the correlation between IGF-<em>1</em>, ZAG, <em>nesfatin</em>-<em>1</em>, HbA<em>1</em>c levels, and T2DM complicated with hypothyroidism was analyzed.Levels of FPG, FINS, TC, TG, LDL, 2hPBG, TPOAb, TgAb, and HOMA-IR in the diabetes group and combined group were all significantly higher than those in the healthy group, while HDL and T4 levels in the diabetes group and combined group were lower than those in the healthy group (P < .05). The levels of FPG, FINS, TC, TG, LDL, 2hPBG, TPOAb, and TgAb in the combined group were significantly higher than those in the diabetes group (P < .05), and the levels of HDL and T4 were lower than those in the diabetes group. In addition, the IGF-<em>1</em> level was positively correlated with ZAG, <em>nesfatin</em>-<em>1</em>, and HbA<em>1</em>c levels in the combined group (P < .05), and IGF-<em>1</em> (OR: 0.964, 95% CI: 0.943-0.983, P = .00<em>1</em>), ZAG (OR: <em>1</em>.298, 95% CI: <em>1</em>.<em>1</em>2<em>1</em>-<em>1</em>.40<em>1</em>, P = .005), <em>nesfatin</em>-<em>1</em> (OR: 0.876, 95% CI: 0.75<em>1</em>-0.90<em>1</em>, P = .002), and HbA<em>1</em>c (OR: <em>1</em>.32<em>1</em>, 95% CI: <em>1</em>.<em>1</em>2<em>1</em>-<em>1</em>.40<em>1</em>, P = .0<em>1</em>2) were independent risk factors for T2DM complicated with hypothyroidism.Regular detection of IGF-<em>1</em>, ZAG, <em>nesfatin</em>-<em>1</em>, and HbA<em>1</em>c levels are of great value for the diagnosis and treatment of patients with T2DM complicated with hypothyroidism.

Essential hypertension (EH) is one of the important problems and comorbidity negatively affects the prognosis of the disease. Substantial thing is investigation of metabolic substances that influence the carbohydrate profile. Aim - investigation of the <em>nesfatin</em>-<em>1</em> activity in patients with Essential hypertension and prediabetes/type2 diabetes. 83 patients with EH were examined and divided into groups according to dysglicemia and abdominal obesity. Significant increasing of <em>nesfatin</em>-<em>1</em> in patients with EH 7,8<em>1</em>±0,26 ng/ml was found comparing to controls 4,54±0,<em>1</em>3 ng/ml, p<0,05. In patients with EH with obesity, without dysglicemia level of <em>nesfatin</em>-<em>1</em> was higher than in obese ones (8,3<em>1</em>±0,<em>1</em>9 ng/ml, 7,44±0,<em>1</em>3 ng/ml correspondebtly (p=0,003)). In patients with EH and dysglicemia the tendency to decreasing of <em>nesfatin</em> in case of accompanied obesity was found. Correlation of <em>nesfatin</em>-<em>1</em> and systolic blood pressure (r=0,34, p<0,05) was revealed in patients with EH, abdominal obesity without dysglicemia. Increasing of <em>nesfatin</em>-<em>1</em> in EH comparing to controls was found. Correlations of <em>nesfatin</em>-<em>1</em> with carbohydrate profile components showed possible involvement of <em>nesfatin</em>-<em>1</em> in carbohydrate disorders. Controversies of <em>nesfatin</em>-<em>1</em> data in patients with EH, dysglicemia, obesity, possibly, connected with polymorbidity and needs further investigation.

A host of gastrointestinal (GI) peptides influence the regulation of vital functions, such as growth, appetite, stress, gut motility, energy expenditure, digestion and inflammation, as well as glucose and lipid homeostasis. Hence, impairments in the synthesis/secretion of glucagon-like peptide-<em>1</em> (GLP-<em>1</em>), leptin, <em>nesfatin</em>-<em>1</em>, glucose-dependent insulinotropic peptide (GIP), ghrelin (acylated and unacylated forms), oxyntomodulin, vasoactive intestinal peptide, somatostatin, cholecystokinin, peptide tyrosine‒tyrosine, GLP-2 and pancreatic polypeptide were previously associated with the development of obesity-related disorders. It is currently emphasized that the beneficial metabolic outcomes associated with the normalization of the gut microbiota (GM) is influenced by increases in GLP-<em>1</em> and peptide YY secretion as well as by decreases in acylated ghrelin production. These effects are associated with reductions in body weight and adiposity in combination with the normalization of glucose and lipid metabolism. However, important questions remain unanswered regarding how GLP-<em>1</em>, peptide tyrosine‒tyrosine, acylated ghrelin and other metabolically relevant GI peptides interact with the GM to modulate the host's metabolic functions. In addition, it is likely that the GM and other biologically active GI peptides influence metabolic functions, such as glucose control, although the mechanisms remain ill-defined. In this review, we investigate how GM and GI peptides influence glucose metabolism in experimental models, such as germ-free animals and dietary interventions. Emphasis is placed on pathways through which GM and GI peptides could modulate intestinal permeability, nutrient absorption, short-chain fatty acid production, metabolic endotoxemia, oxidative stress and low-grade inflammation.

As anorexigenic hormones bombesin and nucleobindin2 (NUCB2)/<em>nesfatin</em>-<em>1</em> decrease food intake in rodents. Both hormones have been described in brain nuclei that play a role in the modulation of hunger and satiety, like the paraventricular nucleus of the hypothalamus (PVN) and the nucleus of the solitary tract (NTS). However, the direct interaction of the two hormones is unknown so far. The aim of study was to elucidate whether bombesin directly interacts with NUCB2/<em>nesfatin</em>-<em>1</em> neurons in the PVN and NTS. Therefore, we injected bombesin intraperitoneally (ip) at two doses (26 and 32nmol/kg body weight) and assessed c-Fos activation in the PVN, arcuate nucleus (ARC) and NTS compared to vehicle treated rats (0.<em>1</em>5M NaCl). We also performed co-localization studies with oxytocin or tyrosine hydroxylase. Bombesin at both doses increased the number of c-Fos positive neurons in the PVN (p<0.05) and NTS (p<0.05) compared to vehicle, while in the ARC no modulation was observed (p>0.05). In the PVN and NTS the number of c-Fos positive neurons colocalized with NUCB2/<em>nesfatin</em>-<em>1</em> increased after bombesin injection compared to vehicle treatment (p<0.05). Moreover, an increase of activated NUCB2/<em>nesfatin</em>-<em>1</em> immunoreactive neurons that co-expressed oxytocin in the PVN (p<0.05) or tyrosine hydroxylase in the NTS (p<0.05) was observed compared to vehicle. Our results show that peripherally injected bombesin activates NUCB2/<em>nesfatin</em>-<em>1</em> neurons in the PVN and NTS giving rise to a possible interaction between bombesin and NUCB2/<em>nesfatin</em>-<em>1</em> in the modulation of food intake.

Background: Diabetes mellitus is the most common metabolic disorder worldwide. We aimed to determine the metabolic and clinical responses to Bunium Persicum (Black Caraway) supplementation in overweight and obese patients with T2DM.

<strong class="sub-title"> Methods: </strong> Participant recruitment took place in the diabetic clinic of Bu-Ali hospital in Zahedan. Due to the eligibility criteria, 60 participants were randomly placed into two groups, namely placebo (<i>n</i> = 30) and BP (<i>n</i> = 30). The supplementation was considered one <em>1</em>000 mg capsule 2 times /day BP by meals (lunch and dinner) for 8 weeks. Physical activity levels, dietary intakes, anthropometric measurements [weight, height, and waist circumference], glycemic indices [fasting blood glucose (FBG) and insulin (FBI)], blood lipids [triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c)], and serum <em>nesfatin</em>-<em>1</em> level were determined. Homeostasis model assessment-insulin resistance (HOMA-IR), Quantitative insulin sensitivity checks index (QUICKI), and Body Mass Index (BMI) were computed.

<strong class="sub-title"> Results: </strong> In comparison with placebo, BP significantly decreased FBG, HOMA-IR, and BMI (<i>P < 0.05</i>). The differences in the FBI, QUICKI, TG, TC, LDL, HDL, WC, and Nesfatin-<em>1</em> were not significant (<i>P > 0.05</i>).

Conclusion: BP supplementation improved serum glucose indices and BMI among overweight and obese T2DM patients. Further trials are needed to confirm results.

<strong class="sub-title"> Trial registration: </strong> Iranian Registry of Clinical Trials (IRCT), IRCT20<em>1</em>8<em>1</em>20704<em>1</em>876N<em>1</em>, Registered <em>1</em>8/0<em>1</em>/20<em>1</em>9, https://irct.ir/trial/35752.

<strong class="sub-title"> Keywords: </strong> Bunium Persicum; Glucose indices; Lipids; Nesfatin-<em>1</em>; Type 2 diabetes.

<em>Nesfatin</em>-<em>1</em> is involved in cardiovascular regulation, stress-related responses. The objective of this study is to investigate the impact of volatile anesthetics on <em>Nesfatin</em>-<em>1</em> levels.

Fourty-two patients aged 30-65 years with the American Society Anesthesiology (ASA) Class I-II who were scheduled for laparoscopic cholecystectomy were included in the study Patients were randomized into two group; desflurane administered group (Group I, n = 2<em>1</em>) and sevoflurane administered group (Group II, n = 2<em>1</em>). For anesthesia maintenance, the patients received 6% desflurane or 2% sevoflurane in 40% O2 and 60% air. The patient's heart rate (HR), mean, systolic and diastolic arterial pressures (MAP, SAP, DAP), peripheral O2 saturation (SpO2) were monitored and recorded before induction, after induction, after intubation, and during extubation. Blood samples were collected before induction (T<em>1</em>), and after extubation when aldrete score was <em>1</em>0 (T2).

Demographic data were similar between the groups. The preoperative levels of nesfatin were similar in the two groups (p = 0.7<em>1</em>5). In desflurane group, post-operative nesfatin levels were similar compared to preoperative levels (p = 0.073). In sevoflurane group, post-operative nesfatin levels were similar (p = 0.<em>1</em>3<em>1</em>). The nesfatin levels (postoperative vs preoperative) were similar between the groups (p = 0.900).

In conclusion, this study results suggest that nesfatin-<em>1</em> levels are not affected by the use of sevoflurane or desflurane in patients undergoing laparoscopic cholecystectomy.

Australian New Zealand Clinical Trials Registry, ACTRN<em>1</em>26<em>1</em>700<em>1</em>023347 , retrospectively registered on <em>1</em>7 July 20<em>1</em>7.